SUBSCRIBE
SUBSCRIBE

Influenza

Pictured: Novavax/Getty Images, STR/NurPhoto
FDA
UPDATE: FDA Lifts Clinical Hold on Novavax’s COVID/Flu Vaccine Candidates, Clears Phase III Trial
Novavax’s shared jumped 12% in pre-market trading on the news.
November 11, 2024
 · 
2 min read
 · 
Annalee Armstrong
Syringe resting on top of a vaccine vial, with more vaccine bottles in the background
Infectious disease
Pfizer, BioNTech’s Mixed Phase III Data Sets Back COVID-Flu Vaccine Candidate
The companies’ late-stage stumble could allow Moderna to widen its lead, with its mRNA-based combination vaccine eliciting superior immune responses against COVID-19 and three influenza strains.
August 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Business people holding a meeting in a conference room
Earnings
Vir Lays Off 25% of Staff, Abandons Most Virus Work and Pivots to Cancer in Sanofi Deal
As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
August 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna’s COVID-Flu Combo Shot Beats Separate Vaccines in Phase III Study
Moderna’s combination vaccine candidate for COVID-19 and influenza outperformed licensed vaccines in older adults, according to late-stage results reported on Monday.
June 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna Secures Up to $750M in Funding from Blackstone to Advance Flu Program
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.
March 27, 2024
 · 
2 min read
 · 
Tristan Manalac
PRESS RELEASES
Press Releases
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
November 15, 2024
 · 
11 min read
Press Releases
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
November 14, 2024
 · 
3 min read
Press Releases
Alveo Technologies Begins Shipping the First Point-of-Need™ Molecular Test for Avian Influenza in Poultry to the EU
November 1, 2024
 · 
4 min read
Press Releases
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
October 31, 2024
 · 
9 min read
Press Releases
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia
October 24, 2024
 · 
3 min read
Press Releases
Quest Diagnostics Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development
October 24, 2024
 · 
5 min read
News
New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
October 18, 2024
 · 
7 min read
Press Releases
CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
October 17, 2024
 · 
11 min read
Press Releases
Update on Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
October 17, 2024
 · 
4 min read
Press Releases
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
October 17, 2024
 · 
5 min read
Press Releases
Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine
October 10, 2024
 · 
3 min read
Press Releases
OPKO Health’s ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million toInitiate Influenza Program
October 9, 2024
 · 
1 min read
Press Releases
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
October 9, 2024
 · 
1 min read
Press Releases
DIOSynVax Unveils Promising Broad Pan-Bird Flu Vaccine Data at Major Influenza Conference
October 8, 2024
 · 
3 min read
Press Releases
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
October 7, 2024
 · 
7 min read
Press Releases
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
October 7, 2024
 · 
8 min read
Press Releases
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
October 1, 2024
 · 
11 min read
Press Releases
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
September 26, 2024
 · 
8 min read
Press Releases
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
September 26, 2024
 · 
5 min read
Press Releases
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
September 24, 2024
 · 
6 min read
Load More